iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
Lenacapavir Safety - Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
 
 
  Download the PDF here
 
Download the PDF here
 

0129241

0129242

0129243

0129244

0129245

0129246

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org